Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of somatostatin in a case of severe hypoglycemia due to nesidioblastosis.

Literature DB >> 6115880

Effects of somatostatin in a case of severe hypoglycemia due to nesidioblastosis.

E Roti, C Ghinelli, P Bandini, C Del Rossi, R Emanuele, G Robuschi, A Gnudi.

Abstract

The Authors have studied the effects of somatostatin (SRIF) treatment in an infant affected by hypoglycemia due to nesidioblastosis. During iv infusion with SRIF we observed a marked increase of blood glucose levels; concomitantly insulin secretion was almost completely suppressed. In contrast, during treatment with protamine zinc-somatostatin (PZ-SRIF), a long acting SRIF preparation, the blood glucose levels did not rise and insulin concentrations were inappropriately elevated. Therefore in this case the long term treatment of hypoglycemia due to nesidioblastosis with PZ-somatostatin was unfeasible.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1981 PMID： 6115880 DOI： 10.1007/BF03350454

Source DB: PubMed Journal: J Endocrinol Invest ISSN： 0391-4097 Impact factor: 4.256

15 in total

1. D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule.

Authors: J Rivier; M Brown; W Vale
Journal: Biochem Biophys Res Commun Date: 1975-07-22 Impact factor: 3.575

2. The response of pancreatic and pituitary hormones to pulses and constant infusion of somatostatin.

Authors: H Leblanc; L A Rigg; S S Yen
Journal: J Clin Endocrinol Metab Date: 1975-12 Impact factor: 5.958

3. Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinomas: a possible diagnostic tool.

Authors: M Lorenzi; J E Gerich; J H Karam; P H Forsham
Journal: J Clin Endocrinol Metab Date: 1975-06 Impact factor: 5.958

4. Dose-response study of the inhibiting effect of somatostatin on growth hormone and insulin secretion in normal subjects and acromegalic patients.

Authors: G Giustina; M Peracchi; E Reschini; E Panerai; M Pinto
Journal: Metabolism Date: 1975-07 Impact factor: 8.694

5. Effect of somatostatin on basal and glucose induced insulin release in five patients with hyperinsulinaemia.

Authors: S Efendić; P E Lins; G Sigurdsson; B Ivemark; P O Granberg; R Luft
Journal: Acta Endocrinol (Copenh) Date: 1976-03

6. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors: C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal: Lancet Date: 1974-04-20 Impact factor: 79.321

Effects of somatostatin in a case of severe hypoglycemia due to nesidioblastosis.

1. D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule.

2. The response of pancreatic and pituitary hormones to pulses and constant infusion of somatostatin.

3. Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinomas: a possible diagnostic tool.

4. Dose-response study of the inhibiting effect of somatostatin on growth hormone and insulin secretion in normal subjects and acromegalic patients.

5. Effect of somatostatin on basal and glucose induced insulin release in five patients with hyperinsulinaemia.

6. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

7. Inhibition of growth hormone release in humans by somatostatin.

8. Inhibition of growth hormone secretion in the rat by synthetic somatostatin.

9. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.

10. Hypoglycemia of infancy and nesidioblastosis. Studies with somatostatin.

1. The hyperinsulinaemic hypoglycaemias in infancy: a study of six cases.

2. Gastroenteropancreatic endocrine tumors.

Review 3. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.